Poor
Not Aligned
Patient Risk:
High
Summary
Major portions of the extracted claims are absent from the provided FDA label content, including key safety statements about combining ibuprofen with antidepressants (especially SSRIs/SNRIs and bleeding risk mechanism), along with urgent-care triage guidance and acetaminophen substitution/comparative GI bleeding claims.
Category Scores
Accurate Statements
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID).
Supported by provided label sections referencing ibuprofen as an NSAID (DOSAGE AND ADMINISTRATION; DRUG INTERACTIONS).
Using the lowest effective ibuprofen dose for the shortest time is a common risk-reduction step.
DOSAGE AND ADMINISTRATION: “Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals”.
Ibuprofen can irritate the stomach.
ADVERSE REACTIONS: “most frequent type of adverse reaction… is gastrointestinal”; and GI complaints including nausea, epigastric pain, heartburn.
Ibuprofen can increase the risk of kidney stress in some people.
ADVERSE REACTIONS/RENAL: includes acute renal failure and decreased creatinine clearance (and related renal reactions).
Unsupported Statements
Using ibuprofen together with many antidepressants is usually possible.
No matching information in the provided label sections.
Using ibuprofen together with antidepressants can increase the risk of certain side effects.
No matching antidepressant-specific interaction or combination safety information in the provided label sections.
The most notable side effect risk when combining ibuprofen with certain antidepressants is bleeding.
Antidepressant-specific bleeding risk is not supported in the provided label sections.
Antidepressants that affect serotonin can increase bleeding risk.
Serotonin/platelet mechanism and antidepressant class mechanism statements are absent from the provided label sections.
SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin-norepinephrine reuptake inhibitors) can make bleeding more likely.
No SSRI/SNRI-specific statements in the provided label sections.
Serotonin helps platelets form clots.
No biochemical mechanism statement is present in the provided label sections.
When SSRIs or SNRIs are combined with an NSAID like ibuprofen, the risk of gastrointestinal bleeding can increase.
No SSRI/SNRI + NSAID GI bleeding guidance is present in the provided label sections.
Some antidepressants may pose a lower bleeding risk than SSRIs/SNRIs.
No antidepressant comparative risk information is present in the provided label sections.
The exact bleeding risk depends on the specific antidepressant and patient factors.
No antidepressant-specific risk stratification is present in the provided label sections.
Patient factors that affect bleeding risk include a history of ulcers or bleeding.
The provided label excerpts do not link ulcer/bleeding history to antidepressant combinations.
People with a prior stomach ulcer or GI bleeding are generally higher risk when combining ibuprofen with antidepressants.
Antidepressant-combination risk stratification is not supported by the provided label excerpts.
People who are older are generally higher risk when combining ibuprofen with antidepressants.
The provided label excerpt supports general caution in elderly for ibuprofen, but not increased risk specifically for antidepressant combinations.
High-dose or frequent ibuprofen use is associated with higher risk when combining ibuprofen with antidepressants.
Dose-related adverse reaction information is present, but not tied to antidepressant combination bleeding risk in the provided label excerpts.
Taking additional blood-thinning or antiplatelet medicines increases risk when combining ibuprofen with antidepressants.
The provided label excerpts discuss interactions with certain anticoagulants/aspirin, but do not specifically address antidepressant co-administration.
Examples of blood-thinning or antiplatelet medicines include aspirin, warfarin, apixaban, and clopidogrel.
Aspirin and warfarin-type anticoagulants are mentioned; apixaban and clopidogrel are not mentioned in the provided label excerpts.
Significant kidney disease or dehydration is associated with higher risk when combining ibuprofen with antidepressants.
No provided label excerpt supports dehydration/kidney disease risk specifically for antidepressant combinations.
Heavy alcohol use is associated with higher risk when combining ibuprofen with antidepressants.
No alcohol-related statements appear in the provided label excerpts.
Avoiding ibuprofen on an empty stomach is a common risk-reduction step.
The provided label says to administer with meals/milk if GI complaints occur, which is not equivalent to a general 'avoid on empty stomach' instruction.
Patients should ask a clinician whether an alternative pain reliever or stomach-protective therapy is safer for the specific antidepressant and health history.
No antidepressant-specific alternative therapy guidance is present in the provided label excerpts.
Urgent care should be sought if there are signs of GI bleeding such as black or tarry stools.
No urgent-care/triage instructions with those specific symptoms are present in the provided label excerpts.
Urgent care should be sought if there is vomiting blood.
No such urgent-care triage instructions are present in the provided label excerpts.
Urgent care should be sought if vomit looks like coffee grounds.
No such urgent-care triage instructions are present in the provided label excerpts.
Urgent care should be sought for unexplained weakness or fainting in the context of possible GI bleeding.
No such urgent-care triage instructions are present in the provided label excerpts.
Urgent care should be sought for severe stomach pain.
No such urgent-care triage instructions are present in the provided label excerpts.
Urgent care should be sought for allergic reactions.
No urgent-care triage instructions are present in the provided label excerpts.
In many cases, clinicians consider acetaminophen (paracetamol) as a pain alternative when on antidepressants.
No acetaminophen alternative guidance tied to antidepressant use appears in the provided label excerpts.
Acetaminophen does not work like an NSAID.
No acetaminophen comparison statements are present in the provided label excerpts.
Acetaminophen generally has a lower GI bleeding risk than ibuprofen.
No comparative GI bleeding risk statements involving acetaminophen are present in the provided label excerpts.
Dosing limits for acetaminophen still matter.
No acetaminophen dosing/limits statements are present in the provided label excerpts.
Antidepressants can affect blood pressure.
No antidepressant-specific blood pressure statements are present in the provided label excerpts.
Antidepressants can cause sedation.
No antidepressant-specific sedation statements are present in the provided label excerpts.
Antidepressants can affect other physiology.
No broad antidepressant physiology statements are present in the provided label excerpts.
Contradictions
Important Omissions
Provided label excerpts include specific drug-interaction precautions for ibuprofen with aspirin (including interference with antiplatelet activity) and warfarin-type anticoagulants (synergistic GI bleeding risk), as well as lithium, diuretics, and methotrexate considerations; the extracted claims largely omit these ibuprofen-specific interaction details and instead focus on antidepressant combinations.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Several high-level combination safety claims regarding antidepressants and bleeding (including SSRIs/SNRIs and serotonin mechanism) are unsupported by the provided ibuprofen label excerpts. Additional unsupported urgent-care triage and acetaminophen substitution/comparative risk statements may mislead clinical decision-making.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Antidepressant–ibuprofen bleeding risk claims (SSRIs/SNRIs, serotonin/platelet mechanism, and urgent-care/acetaminophen guidance) are absent from the provided FDA label excerpts.
Suggested Improvement
Limit claims to what is supported in the provided ibuprofen labeling (e.g., general NSAID/GI adverse reactions; ibuprofen dose minimization; GI complaint administration with meals/milk; and interaction precautions with aspirin and warfarin-type anticoagulants). Remove antidepressant-specific bleeding mechanism and triage guidance unless supported by the provided label sections.